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ABSTRACT 
Objective: To characterize the differences in stability of L-adrenaline in adrenaline ampoules from different manufacturers that are used by the 
Israel Defense Forces (IDF). 
Methods: Adrenaline ampoules from three different vendors (Products A, B and C; 52, 13, and 19 batches, respectively) were purchased by the IDF 
and were stored under the recommended storage conditions (room temperature) for different time periods. The content of L-adrenaline in these 
samples was determined using a chiral high-performance liquid chromatography (HPLC) assay with UV detection. 
Results: The three analyzed drug products showed very dissimilar patterns of L-adrenaline degradation. The content of L-adrenaline in Product C 
was variable and declined below the 85% threshold much earlier than at the end of the 24-months storage period. Products A and B had less 
variable content of L-adrenaline and were more stable. 
Conclusion: L-adrenaline is prone to degradation in solution. Its content in adrenaline ampoules from certain vendors can decline rapidly, below 
the stipulated threshold, and compromise their clinical effectiveness (e. g., during resuscitation). Stability of adrenaline ampoules from individual 
vendors should be analyzed at different storage conditions, using a chiral HPLC-based assay, to define the shelf-life period that can differ 
substantially between the vendors. 
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Adrenaline (Epinephrine) is used to treat a number of conditions 
including anaphylaxis, cardiac arrest, and superficial bleeding. 
Adrenaline is a chiral compound, and only the L-isomer has 
significant pharmacological activity and is incorporated as an active 
component into adrenaline formulations [1, 2]. L-adrenaline is 
available in a form of aqueous solution filled into ampoules (used 
mainly by the health care professionals) or auto injectors (for self-
injection by the patients). 
L-adrenaline is relatively unstable in aqueous solutions and 
degrades via a number of pathways, including oxidation, 
racemization (to D-adrenaline) and reaction with the inactive 
formulation ingredients (e. g., bisulfite) [3-7]. These chemical 
reactions and pathways have been investigated thoroughly over the 
past decades. Different methods have been suggested to improve the 
drug’s chemical stability, such as maintaining acidic pH, storage at 
low temperature, protection from light and use of antioxidants other 
than bisulfite [5, 8-11]. 
During the process of registration of a new drug product, the 
pharmaceutical company is required to investigate and report its 
chemical stability to the national regulator. The active compound in 
these stability studies can be quantified using the manufacturer’s in-
house analytical method, or a method adopted from the relevant 
Pharmacopoeia: the United States, British or European 
Pharmacopoeia (USP/BP/EP), depending on the geographic region 
of marketing. Prior to 2018, all these Pharmacopeias did not require 
separate quantification of adrenaline enantiomers in the drug 
products, despite the availability of several stereo-selective 
analytical methods [2, 4, 12-14]. Since 2018, the BP requires a 
separate quantification of L-adrenaline (that should be>85% of the 
labeled amount in the injectable adrenaline drug products) [15], 
using a chiral High Performance Liquid Chromatography (HPLC) 
method that is similar to the method used in our laboratory for more 
than 20 y [14], in addition to the old non-chiral HPLC assay [15]. USP 
has not yet updated the monograph of adrenaline/epinephrine [16] 
to allow quantification of the individual enantiomers. 
Based on the above-mentioned Pharmacopoeial requirements, 
adrenaline injections from majority of manufacturers were 
approved based on the total content of adrenaline enantiomers, 
without quantification of L-adrenaline initial content and its change 
during the storage period. Therefore, the quality and efficacy of 
adrenaline injections from different vendors can be compromised, 
especially towards the end of their shelf-life, if a substantial amount 
of L-adrenaline undergoes racemization to the D-enantiomer. 
The Israel Defense Forces (IDF) use adrenaline ampules for 
administration by the Advance Life Support (ALS) providers, in the 
clinics and in pre-hospital field conditions. Adrenaline ampoules, 
and additional drug products that are stored and used at the 
uncontrolled field conditions, are subjected to a dedicated stability 
surveillance program. Until 2016, the IDF have purchased 
adrenaline ampoules from a single local manufacturer (A). These 
ampoules were made of amber glass, filled under inert gas, and 
contained 1 mg/ml L-adrenaline in aqueous solution with acidic pH 
and sodium metabisulfite, that served as an antioxidant 
preservative. This Product’s shelf-life period has been altered 
several times over the years, reflecting the comprehension of L-
adrenaline degradation kinetics and the assays that were used for its 
assessment. After cessation of manufacture of Product A, adrenaline 
ampoules were purchased from 2 different European manufacturers 
(B and C). This report describes significant differences in the 
stability of L-adrenaline in these three Products. It focuses on the 
content of L-adrenaline only, which is a single indicator of the 
clinical effectiveness of the studied samples. 
The following materials were used: L-adrenaline bitartrate and 
potassium chloride were from Sigma (St. Louis, MO). Glacial acetic acid 
and HPLC-grade acetonitrile were from J. T. Baker (Deventer, Holland). 
Water was purified with a tandem RiOs (reverse osmosis)/Milli-Q 
Gradient A-10 system (Millipore, Molsheim, France). All other 
chemicals used in this study were of analytical or HPLC grade. 
The HPLC method was based on a chiral Shodex ODS 5 mm column, 
150x4.6 mm (Showa Denko K. K., Tokyo, Japan) and HP1100 
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chromatographic system (Hewlett Packard, Palo Alto, CA) interfaced to 
an HP Chem Station [14]. The mobile phase was 0.2 M potassium 
chloride in water: 0.2 M potassium chloride and 0.4% (v/v) acetic acid 
in water: acetonitrile (96:1:3, v/v). The samples were diluted 1:20 in 
the mobile phase, and 50 μL of these diluted samples were injected. 
The column temperature was 10 °C, the flow rate was 0.7 ml/min, the 
run time was 20 min, and the detection wavelength was 280 nm. This 
method undergo a thorough validation in our laboratory [14], and the 
limit of detection and limit of quantitation values for L-adrenaline 
were 0.11 μg/ml and 0.36 μg/ml, respectively. 
In this study, we analyzed 52, 13, and 19 individual batches of 
Products A, B and C. These batches were purchased by the IDF, and 
stored under the recommended storage conditions (room 
temperature). Majority of these batches were stored beyond their 
shelf-life and were analyzed more than once during their storage 
period, as required by the IDF drugs’ stability surveillance program. 
Data from the most recent set of assays are shown in fig. 1. 
The shelf-life of Products B and C is 24 mo, as defined by the 
manufacturer. The shelf-life of Product A has been changed several 
times, from 2 y (before 2006) to 6 mo (from 2006, for several years), 
and to 18 mo (during the last years of its production, until end of 
manufacture in 2016). In the years 1997-2016, the Product A was 
produced for the IDF with enhanced content of the active compound 
(103-115% of the stipulated content of L-adrenaline). This 
manufacturing change prolonged the period of L-adrenaline content 
above 85% of the stipulated strength (i.e., 0.85 mg/ml), which was 
set as a threshold for a shelf-life of this drug product in the IDF. 
Product A maintained stability for 24 mo, but not longer, and was 
characterized by apparently small inter-batch variability of L-
adrenaline content, during the drug product shelf-life and beyond it. 
Product B showed a remarkably stable content of L-adrenaline, which 
remained well above 85% of the stipulated content even after 24 mo 
of storage, as well as small inter-batch variability of L-adrenaline 
content, similar to that of Product A. A relatively small number of 
batches of this drug product were evaluated in our laboratory, and 
data from additional batches are needed to verify this trend.  
L-adrenaline in Product C apparently undergo rapid degradation 
during storage. The L-adrenaline content in Product C declined 
below 90% and below 85% (which were set as the shelf-life 
thresholds for this drug product by the manufacturer and the IDF, 
respectively) much earlier than at the end of the 24-months storage 
period. We found large variability in the drug content between the 
individual batches of Product C, with 45% and 98% out-of-trend 
results after 8.5 and 50 mo, of storage, respectively. This finding 
indicates a lack of reproducibility in the manufacturing process of 
this drug product or/and non-uniform drug degradation rate in the 
individual batches. 
Three drug products of adrenaline ampoules that were studied in 
our laboratory showed very dissimilar patterns of L-adrenaline 
degradation. The degradation kinetics of Product A matches the 
previously published data [14], and is coherent with the 
manufacturer’s stability data upon which the 24 mo shelf-life at the 
room temperature has been set. Product B appears to be more 
stable, and has slower degradation kinetics, as compared to Product 
A, but has the same 24-months-long declared shelf-life. 
The content of the pharmacologically-active L-adrenaline isomer in 
Product C declined rapidly during its storage at the recommended 
conditions, potentially leading to compromised efficacy and clinical 
effectiveness of this drug product, especially at the second half of its 
stipulated storage period. This problem is apparently aggravated in 
the pre-hospital ALS settings when the drug product can be exposed 
to the non-recommended storage conditions (e. g., extremes of 
temperature). Products A and B are more stable and thus preferable 
for ALS use in different settings. 
The reason for the differences in the drug degradation kinetics 
between the studied products is not known. Apparently, it does not 
originate from the differences in the pH, exposure to light, or 
compromised sealing (all the studied drug products comprise amber 
glass ampules, filled with inert gas, and maintain steady pH during 
their storage; data not shown). It may be related to the inactive 
components of the studied formulations, or even trace 
concentrations of elements diffusing from glass containers and 
triggering the degradation of adrenaline [7, 17]. Further 
investigation is needed to reveal the factors that govern the 
degradation pathways of L-adrenaline in the studied drug products 
and to identify the most stable formulation of this drug. This 
investigation would benefit from adoption of uniform standards of 
L-adrenaline injections quality control, by all the Pharmacopeias and 
manufacturers, based on a chiral method for separate quantitation 




Fig. 1: The content of the L-adrenaline in the individual batches of products A, B and C. A. 
 
Product A (Israeli vendor, manufacture discontinued in 2016). B. 
Product B (European vendor, procurement started in 2017). C. 
Product C (European vendor, procurement started in 2017). The 
dots are the individual assayed batches. The red line represents 
the threshold for a shelf-life of this drug product in the IDF (L-
adrenaline content above 85% of the stipulated amount). The same 
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